PATENT CLAIM ANALYSIS

Application Number: 16294615
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to treating, a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIT inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIE inhibitor.

Claim (Index 12):
The method of claim ii, wherein the cytogenetic alteration is selected from the group consisting of:\n 47,XY,+21;46,XY; 45,XX,\u22127; 46,XY,t(8;21)(q22;q22); 49,XX,+8,+8,inv(16)(03.1q22),+21; 46,XX,inv(16)(0.3q22)/46,)0c; 46,XY,inv(16)(03q22); 46,XX,t(2;13)(p23;q 12 )/46,XX; 45,XY,inv(3)(c121q26.2),\u22127/46,XY; 47,XY,+4,inv(5)(0.5q13)/47,s1,\u22124,+22; 46,XX,t(11;19)(q23;03.1); 46,XX,t(6;11)(q27;q23)/46,XX; and 46,XX,t(1;17)(03;q25),t(9;11)(p22;q23).

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.56757
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13513659', '15234195', '15448737', '14212418', '11632231']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8682145272215411
- 35 USC 102 Novelty (BERT): 0.5674537159252275
- Combined Prediction Score: 0.8381384460919098
- Mean Citation Score: 507.42187200000006
- Max Citation Score: 701.1846
- Similarity Product: 346.3343416445732

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test